Published in Reproduction on April 04, 2008
Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int (2010) 2.12
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther (2012) 1.07
Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci (2010) 0.99
Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol (2010) 0.89
Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes. Br J Pharmacol (2011) 0.89
Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol (2011) 0.83
Expression of Angiotensin II Receptor-1 in Human Articular Chondrocytes. Arthritis (2012) 0.82
Heterodimerization of apelin receptor and neurotensin receptor 1 induces phosphorylation of ERK(1/2) and cell proliferation via Gαq-mediated mechanism. J Cell Mol Med (2014) 0.80
Psmir: a database of potential associations between small molecules and miRNAs. Sci Rep (2016) 0.77
VEGF in the crosstalk between human adipocytes and smooth muscle cells: depot-specific release from visceral and perivascular adipose tissue. Mediators Inflamm (2013) 0.77
Salvianolic acid A inhibits angiotensin II-induced proliferation of human umbilical vein endothelial cells by attenuating the production of ROS. Acta Pharmacol Sin (2011) 0.77
Luteolin Inhibits Angiotensin II-Stimulated VSMC Proliferation and Migration through Downregulation of Akt Phosphorylation. Evid Based Complement Alternat Med (2015) 0.75
The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia. Int J Endocrinol (2015) 0.75
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res (2000) 2.83
Human ovarian tissue cryopreservation: quality of follicles as a criteria of effectiveness. Reprod Biomed Online (2010) 2.46
p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet (1995) 1.84
Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol (2002) 1.72
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res (2001) 1.59
Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol (1999) 1.58
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol (2005) 1.58
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature (1985) 1.53
Long-term morbidity following axillary dissection in breast cancer patients--clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat (2000) 1.45
p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol (1999) 1.45
Human ovarian tissue vitrification versus conventional freezing: morphological, endocrinological, and molecular biological evaluation. Reproduction (2009) 1.42
Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis. Br Med J (Clin Res Ed) (1983) 1.40
[Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer]. Geburtshilfe Frauenheilkd (1993) 1.39
[Diabetes screening in pregnant patients with different risk factors. Benefits, therapeutic success, consequences]. Z Geburtshilfe Neonatol (1996) 1.39
Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol (2009) 1.33
Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol (2002) 1.32
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics (2001) 1.23
Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med (2001) 1.22
Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol (2001) 1.17
Germ cell differentiation in the marmoset (Callithrix jacchus) during fetal and neonatal life closely parallels that in the human. Hum Reprod (2008) 1.16
Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat (2013) 1.14
Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat (2010) 1.13
p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res (1998) 1.13
Hemicellulose-degrading bacteria and yeasts from the termite gut. J Appl Bacteriol (1996) 1.12
Effect of active immunization to luteinizing hormone releasing hormone on serum and pituitary gonadotrophins, testes and accessory sex organs in the male rat. J Endocrinol (1974) 1.12
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol (2013) 1.09
Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer (1992) 1.08
MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol (1997) 1.08
Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology (2000) 1.06
KiSS-1 in the mammalian ovary: distribution of kisspeptin in human and marmoset and alterations in KiSS-1 mRNA levels in a rat model of ovulatory dysfunction. Am J Physiol Endocrinol Metab (2009) 1.06
Immunoexpression of aquaporin-1 in the efferent ducts of the rat and marmoset monkey during development, its modulation by estrogens, and its possible role in fluid resorption. Endocrinology (1998) 1.05
Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol (2008) 1.05
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer (2000) 1.04
Differential expression of estrogen receptor-alpha and -beta and androgen receptor in the ovaries of marmosets and humans. Biol Reprod (2000) 1.03
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer (1999) 1.03
Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study. Breast Cancer Res Treat (2011) 1.01
Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol (2000) 1.01
Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol (1989) 1.00
Ultrasound-guided large-core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumour classification. Br J Cancer (2005) 1.00
Development and validation of a new monoclonal antibody to mammalian aromatase. J Endocrinol (2002) 1.00
The neonatal period: a critical interval in male primate development. J Endocrinol (1996) 0.99
Immunolocalisation of oestrogen receptor-alpha within the testis and excurrent ducts of the rat and marmoset monkey from perinatal life to adulthood. J Endocrinol (1997) 0.99
Long-term results after operative correction of vaginal aplasia. Am J Obstet Gynecol (1996) 0.98
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol (2010) 0.98
Pediatric generalists and subspecialists: determinants of career satisfaction. Pediatrics (2001) 0.98
Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol (2004) 0.98
Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology (2001) 0.97
Marmoset spermatogenesis: organizational similarities to the human. Int J Androl (2000) 0.95
Angiogenesis in the human corpus luteum: localization and changes in angiopoietins, tie-2, and vascular endothelial growth factor messenger ribonucleic acid. J Clin Endocrinol Metab (2000) 0.95
A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations? Eur J Cancer (2011) 0.94
Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol (2000) 0.94
p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology (1999) 0.94
Angiogenesis in the human corpus luteum: simulated early pregnancy by HCG treatment is associated with both angiogenesis and vessel stabilization. Hum Reprod (2001) 0.94
Physiological roles of chicken LHRH-I and -II in the control of gonadotrophin release in the domestic chicken. J Endocrinol (1990) 0.94
Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin. Int J Cancer (1998) 0.93
Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. Hum Reprod (1997) 0.93
Spatio-temporal source imaging reveals subcomponents of the human auditory mismatch negativity in the cingulum and right inferior temporal gyrus. Neurosci Lett (2001) 0.93
Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40). J Clin Endocrinol Metab (2001) 0.92
A multiplex one-step real-time RT-PCR assay for influenza surveillance. Euro Surveill (2011) 0.92
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol (2013) 0.92
Location and developmental regulation of androgen receptor in primate ovary. Hum Reprod (1997) 0.91
HCG stimulation of testicular LHRH-like activity. Nature (1980) 0.91
New prospects for luteinising hormone releasing hormone as a contraceptive and therapeutic agent. Br Med J (Clin Res Ed) (1982) 0.91
Sertoli-Leydig cell communication via an LHRH-like factor. Nature (1981) 0.91
Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab (1986) 0.91
Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol (2002) 0.90
Effect of neonatal gonadotropin-releasing hormone antagonist administration on sertoli cell number and testicular development in the marmoset: comparison with the rat. Biol Reprod (2000) 0.90
Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol (2004) 0.90
Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. Br Med J (Clin Res Ed) (1984) 0.89
Role of the neonatal period of pituitary-testicular activity in germ cell proliferation and differentiation in the primate testis. Hum Reprod (2003) 0.88
[Stage 3 recommendations--the early recognition of breast cancer in Germany. Abridged version for medical practitioners]. Radiologe (2003) 0.88
Intratesticular hormone levels and the route of secretion of hormones from the testis of the rat, guinea pig, monkey and human. Int J Androl (1993) 0.88
Angiogenesis in the primate ovary. Reprod Fertil Dev (2001) 0.88
Determination of nomifensine by a sensitive radioimmunoassay. Br J Clin Pharmacol (1977) 0.88
Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat (2011) 0.88
Clinical applications of LHRH analogues. Baillieres Clin Endocrinol Metab (1987) 0.87
Ultrasound assessment of tension-free vaginal tape (TVT). Ultraschall Med (2010) 0.87
Chicken ovalbumin upstream promoter transcription factor (COUP-TF): an orphan steroid receptor with a specific pattern of differential expression in human ovarian cancer cell lines. Gynecol Oncol (1993) 0.86
Development of a duplex real-time PCR for differentiation between E. coli and Shigella spp. J Appl Microbiol (2011) 0.86
Testicular changes during infantile 'quiescence' in the marmoset and their gonadotrophin dependence: a model for investigating susceptibility of the prepubertal human testis to cancer therapy? Hum Reprod (2002) 0.86
Cell death during natural and induced luteal regression in mares. Reproduction (2002) 0.86
Hypothalamic pulse generators. Recent Prog Horm Res (1985) 0.86
Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol (1998) 0.86
Acrosomal status and mitochondrial activity of human spermatozoa vitrified with sucrose. Reproduction (2008) 0.85
The role of endogenous gonadotropin-releasing hormone in the control of luteinizing hormone and testosterone secretion in the juvenile male monkey, Macaca fascicularis. Biol Reprod (1985) 0.85
Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr (1997) 0.85
Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate. J Clin Endocrinol Metab (2000) 0.85
Effect of treatment for 1 year with a luteinizing hormone-releasing hormone agonist on ovarian, thyroidal, and adrenal function and menstruation in the stumptailed monkey (Macaca arctoides). Endocrinology (1983) 0.85
Interaction between alcohol dehydrogenase II gene, alcohol consumption, and risk for breast cancer. Br J Cancer (2002) 0.85
Mid-luteal angiogenesis and function in the primate is dependent on vascular endothelial growth factor. J Endocrinol (2001) 0.85